Latest News & Features
Europe
Teva Pharmaceutical Industries has claimed victory in a patent revocation action brought by generic drug maker Mylan in the Hague over its blockbuster Copaxone drug, used in the treatment of multiple sclerosis. 4 October 2013
article
Swedish law firm Vinge has hired IP specialist Ulf Dahlgren to its Stockholm office from rivals Lindahl, following Håkan Borgenhäll’s move from the same firm in April. 3 October 2013
Americas
Mylan Inc will be forced to divest injectable generic drugs before it can complete a proposed $1.85 billion acquisition of Agila Specialities Global Pte Ltd and Agila Specialties Pvt Ltd after the FTC applied conditions to the deal. 2 October 2013
Americas
US law firm Baker Botts has expanded its Houston office with the addition of IP litigator Nicolas Barzoukas. 1 October 2013
Americas
India’s drug patent policy has been slammed by US companies who are insisting that action be taken in order to improve trade relations. 30 September 2013
Big Pharma
The annual International Association for the Protection of IP (AIPPI) conference in Helsinki, Finland, assessed the potential problems for pharmaceutical companies trying to brand their medicinal products. 30 September 2013
Biotechnology
With a track record of successful innovation, Munich is one of the leading lights of European biotech. LSIPR went to visit. 30 September 2013
Americas
Developing new drugs is time-consuming and expensive. DelMar Pharma researches old drugs and establishes new IP around them to streamline the process. LSIPR spoke to chief executive Jeffrey Bacha about the company’s approach. 30 September 2013
Americas
A federal judge has denied AstraZeneca’s motions to dismiss claims challenging its pay-for-delay deals with three generic pharmaceutical companies in connection to heartburn drug Nexium. 27 September 2013
Americas
A US company which provides secure personal medical records online has filed a patent infringement case against a rival health-care company. 26 September 2013